Welcome to our dedicated page for The Cooper Companies news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on The Cooper Companies stock.
The Cooper Companies, Inc. (NYSE: COO) is a global medical device company specializing in improving quality of life through innovative products and services. Headquartered in San Ramon, CA, Cooper operates through two main business units: CooperVision and CooperSurgical.CooperVision is a leader in the contact lens industry, offering a diverse range of high-quality contact lenses, including spherical, multifocal, toric, and specialty lenses. With brands like Proclear, Biofinity, MyDay, and Clariti, CooperVision commands roughly one-fourth of the US contact lens market. The company is committed to providing excellent practitioner support, ensuring that both users and professionals benefit from their cutting-edge solutions.
CooperSurgical, founded in 1990, focuses on women's health and fertility, offering market-leading products and treatment options. The division supplies clinicians with over 600 medical devices and treatment solutions related to reproductive care, fertility, and women's health. Notably, CooperSurgical owns Paragard, the only hormone-free IUD available in the US, holding a 17% share of the US IUD market. Additionally, CooperSurgical has the largest medical device coverage for the entire IVF cycle.
With a workforce of over 15,000 employees and products available in more than 130 countries, CooperCompanies is dedicated to delivering shareholder value while enhancing the lives of individuals globally. The company continues to innovate and expand, recently achieving record annual revenues and strong earnings. Noteworthy advancements include a four-for-one stock split set to become effective on February 16, 2024, and partnerships like that with Fulgent Genetics to offer exclusive newborn genetic screening panels through Cord Blood Registry.
Cooper's fiscal year 2023 showcased significant milestones, including double-digit organic growth in their fertility segment and strong performance in contact lenses. As they move into fiscal year 2024, Cooper remains focused on their strategic objectives: gaining market share, driving profitability, and launching innovative products and services.
For more information, please visit CooperCompanies.
Vuzix Corporation (NASDAQ: VUZI) announces the deployment of its M400 Smart Glasses at CooperVision's distribution center in West Henrietta, NY. This implementation, utilizing LogistiVIEW's Vision+ augmented reality software, aims to enhance operational efficiency through hands-free picking guidance. The 275,000 sq ft facility manages over 120,000 contact lens products. Key executives from both companies highlight the positive impact of this technology in streamlining warehouse operations.
TMRW Life Sciences announces the appointment of Brian E. Miller, PhD, as Senior Vice President of Sales, effective March 5, 2021. With over 25 years in the fertility industry, Miller will drive the deployment of TMRW's innovative technology to U.S. fertility clinics and aid in the development of new products. Previously at CooperSurgical, he has extensive experience in biotech and pharma sales. His appointment follows TMRW's commercial launch in February 2021, as the company aims to revolutionize cryo-management in IVF with its automated platform.
CooperCompanies reported a 5% year-over-year revenue growth in Q1 fiscal 2021, reaching $680.5 million. CooperVision's revenue grew 4% to $507.0 million, while CooperSurgical increased 8% to $173.5 million. GAAP diluted EPS rose to $42.31, up from $40.49 last year. The company announced fiscal 2021 guidance, projecting total revenue between $2,800 million and $2,845 million. Operating margin improved to 20%, while free cash flow was $91.8 million. Despite positive performance, COVID-19 remains a risk factor for future operations.
CooperCompanies (NYSE: COO) will participate in the KeyBanc Life Sciences MedTech Investor Forum on March 24, 2021. Brian Andrews, the Executive Vice President and CFO, will represent the company in a virtual session starting at 1:15 PM ET. A live webcast will be accessible on Cooper's Investor Relations website, with an archived audio file available later that day. CooperCompanies is a global leader in medical devices, operating through CooperVision and CooperSurgical, and is headquartered in San Ramon, CA.
CooperCompanies (NYSE: COO) has acquired Safe Obstetric Systems, a UK-based medical device manufacturer, for approximately £37.5 million in cash, plus a potential contingent payment of up to £10 million based on future revenue growth. The acquisition centers on the Fetal Pillow®, an FDA-approved device that aids in cesarean deliveries. Generating £3.5 million in revenue in 2020, the acquisition is expected to have a neutral impact on Cooper's non-GAAP earnings per share for fiscal 2021. This move aligns with CooperSurgical's mission to enhance women's healthcare.
CooperCompanies (NYSE: COO) will participate in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021. The session, representing CooperVision, will be led by Executive Vice President and COO Daniel McBride at 1:10 PM ET. Investors can access a live webcast through CooperCompanies' Investor Relations webpage, with an archived audio replay available later that day. CooperCompanies operates globally, focusing on vision care and women's health through its divisions, CooperVision and CooperSurgical, with a workforce exceeding 12,000.
CooperCompanies (NYSE: COO) will announce its first quarter 2021 financial results on March 4, 2021, at 4:15 PM ET. Following the announcement, a conference call will take place at 5:00 PM ET to discuss the financial results and recent developments. The conference call can be accessed by dialing 855-643-4430 in the U.S. or 707-294-1332 internationally, with the passcode 'Cooper'. A replay of the call will be available until March 11, 2021. CooperCompanies operates in vision care and women's health, with a global workforce exceeding 12,000.
EssilorLuxottica and CooperCompanies have announced a joint venture to acquire SightGlass Vision, a U.S. company innovating spectacle lenses to combat myopia progression in children. This 50/50 venture aims to leverage both companies' expertise to enhance the commercialization of SightGlass Vision's lenses, complementing existing products like Essilor's Stellest lens and CooperVision's MiSight. Myopia affects 2.6 billion globally, expected to rise to 5 billion by 2050, making this collaboration essential in addressing this eye health crisis.
CooperSurgical has acquired California-based AEGEA Medical, known for its FDA-approved Mara™ Water Vapor Ablation System. This strategic acquisition enhances CooperSurgical's portfolio in women's healthcare, focusing on in-office treatments for heavy menstrual bleeding. The Mara system offers a two-minute, effective solution, demonstrated by clinical trials to improve quality of life for patients. With 99% of users reporting improved well-being, the acquisition aligns with CooperSurgical's commitment to innovative healthcare solutions.
CooperCompanies Achieves Great Place to Work Certification
On January 26, 2021, CooperCompanies announced that it has been recognized as a Great Place to Work-Certified™ organization for the third consecutive year. Employees rated the company highly for attributes such as pride, camaraderie, and respect. Notably, 91% of employees felt welcomed upon joining. President Albert White emphasized the importance of a supportive culture, while Great Place to Work highlighted Cooper's commitment to a positive employee experience. Cooper operates in the medical device sector, focusing on vision care and women’s health.
FAQ
What is the current stock price of The Cooper Companies (COO)?
What is the market cap of The Cooper Companies (COO)?
What does The Cooper Companies, Inc. specialize in?
Where is The Cooper Companies, Inc. headquartered?
What are some of CooperVision's popular contact lens brands?
What makes CooperSurgical unique in the women's health market?
How many employees does The Cooper Companies, Inc. have?
What recent financial achievements has CooperCompanies reported?
In how many countries are CooperCompanies’ products available?
What recent partnerships has CooperSurgical announced?
What are CooperCompanies' strategic objectives for fiscal year 2024?